Citadel Advisors - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 169 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$2,873,776
-37.9%
104,425
-23.5%
0.00%
-100.0%
Q2 2023$4,629,749
-90.6%
136,450
-90.0%
0.00%
-90.9%
Q1 2023$49,294,255
+29.7%
1,370,046
+60.7%
0.01%
+22.2%
Q4 2022$38,002,789
-14.5%
852,654
-46.1%
0.01%
-10.0%
Q3 2022$44,453,000
-4.9%
1,581,394
-8.8%
0.01%
-16.7%
Q2 2022$46,754,000
-0.8%
1,734,227
+25.3%
0.01%
+20.0%
Q1 2022$47,129,000
-4.5%
1,383,713
+8.4%
0.01%0.0%
Q4 2021$49,334,000
-15.5%
1,276,756
+18.1%
0.01%
-23.1%
Q3 2021$58,361,000
+166.9%
1,080,961
+65.3%
0.01%
+160.0%
Q2 2021$21,865,000
-13.8%
653,871
-46.9%
0.01%
-16.7%
Q1 2021$25,365,000
-12.8%
1,231,316
-25.8%
0.01%
-14.3%
Q4 2020$29,092,000
+623.9%
1,660,516
+512.6%
0.01%
+600.0%
Q3 2020$4,019,000
+55.6%
271,049
+36.5%
0.00%
Q2 2020$2,583,000
+3755.2%
198,608
+396.4%
0.00%
Q1 2020$67,000
-37.4%
40,011
-16.9%
0.00%
Q4 2019$107,000
+296.3%
48,139
+282.1%
0.00%
Q3 2019$27,000
-25.0%
12,600
-5.3%
0.00%
Q2 2019$36,000
-61.7%
13,300
-30.4%
0.00%
Q1 2019$94,00019,1000.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q1 2022
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders